Current Report Filing (8-k)
February 03 2020 - 7:58AM
Edgar (US Regulatory)
0000064803
false
0000064803
2020-02-03
2020-02-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
|
February 3, 2020
|
CVS HEALTH CORPORATION
(Exact name of registrant as specified
in its charter)
Delaware
|
001-01011
|
05-0494040
|
(State or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
One CVS Drive, Woonsocket, Rhode Island
|
02895
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code:
(401) 765-1500
Former name or former address, if changed since last report: N/A
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share
|
CVS
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
|
o
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
o
|
Section
5 – Corporate Governance and Management
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
(b)
To the extent applicable, the information in the below Item 8.01 is incorporated by reference herein.
Section
8 – Other Events
CVS Health Corporation (“CVS Health”)
today announced upcoming changes to its Board of Directors (the “Board”). Richard “Dick” Swift,
Richard Bracken and Mark Bertolini will not stand for re-election at CVS Health’s upcoming Annual Meeting of Stockholders
(the “Annual Meeting”). Following the Annual Meeting, the Board will then be reduced to 13 from 16 directors,
in order to further align with corporate governance best practices.
A copy of the press release dated February 3, 2020 is attached
hereto as Exhibit 99.1 and incorporated by reference herein.
Section 9 –
Financial Statements and Exhibits
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
INDEX TO EXHIBITS
99.1 Press Release of CVS Health Corporation dated February 3, 2020
104 Cover
Page Interactive File (the cover page tags are embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CVS HEALTH CORPORATION
|
|
|
|
Date: February 3, 2020
|
By:
|
/s/ Colleen M. McIntosh
|
|
|
Colleen M. McIntosh
|
|
|
Senior Vice President and Corporate Secretary
|
CVS Health (NYSE:CVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CVS Health (NYSE:CVS)
Historical Stock Chart
From Apr 2023 to Apr 2024